INS and hyperinsulinemic hypoglycemia: Furthermore, as to the point that the insulin-related pathway was DOWN for both WO and MXD, diazoxide, the only drug approved by the U.S. Food and Drug Administration for the treatment of hyperinsulinemic hypoglycemia, has been shown to increase blood glucose by inhibiting insulin secretion through opening of ATP-sensitive potassium (KATP) channels.